TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Autolus Therapeutics ( (AUTL) ) has provided an announcement.
On November 7, 2025, Autolus Therapeutics announced the resignation of Rob Dolski as Principal Accounting Officer, with Patrick McIlvenny appointed to the role effective the same day. The company reported third-quarter 2025 financial results, including $21.1 million in net product revenue for AUCATZYL® and 60 authorized treatment centers. Autolus is advancing its obe-cel therapy for pediatric r/r B-ALL and severe lupus nephritis, with promising clinical data and FDA designations supporting further trials. Leadership changes aim to bolster commercial growth and operational efficiency.
The most recent analyst rating on (AUTL) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.
Spark’s Take on AUTL Stock
According to Spark, TipRanks’ AI Analyst, AUTL is a Neutral.
Autolus Therapeutics’ overall stock score is primarily influenced by its financial performance, which shows strong revenue growth but significant profitability challenges. The earnings call provided positive insights into product sales and regulatory progress, but high costs and market access issues remain concerns. Technical indicators suggest a bearish trend, and valuation metrics are unfavorable due to the company’s unprofitability.
To see Spark’s full report on AUTL stock, click here.
More about Autolus Therapeutics
Autolus Therapeutics is an early commercial-stage biopharmaceutical company focused on developing, manufacturing, and delivering next-generation programmed T cell therapies. The company is primarily involved in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) and other severe autoimmune diseases, with a significant market focus on expanding access to CAR T therapies.
Average Trading Volume: 3,699,978
Technical Sentiment Signal: Sell
Current Market Cap: $351.3M
Find detailed analytics on AUTL stock on TipRanks’ Stock Analysis page.